Free Trial
NASDAQ:CERS

Cerus (CERS) Stock Price, News & Analysis

$1.84
-0.01 (-0.54%)
(As of 05/24/2024 ET)
Today's Range
$1.83
$1.88
50-Day Range
$1.62
$2.04
52-Week Range
$1.21
$3.08
Volume
407,928 shs
Average Volume
1.16 million shs
Market Capitalization
$340.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.83

Cerus MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
108.3% Upside
$3.83 Price Target
Short Interest
Healthy
3.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Cerus in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$372,912 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.08) to ($0.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.07 out of 5 stars

Medical Sector

369th out of 917 stocks

Surgical & Medical Instruments Industry

49th out of 96 stocks

CERS stock logo

About Cerus Stock (NASDAQ:CERS)

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

CERS Stock Price History

CERS Stock News Headlines

Q1 2024 Cerus Corp Earnings Call
Cerus: Q1 Earnings Snapshot
CERS Apr 2024 3.000 call
See More Headlines
Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/02/2024
Today
5/25/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:CERS
CUSIP
15708510
Employees
625
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$3.83
High Stock Price Target
$5.00
Low Stock Price Target
$2.50
Potential Upside/Downside
+108.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-37,490,000.00
Pretax Margin
-19.16%

Debt

Sales & Book Value

Annual Sales
$156.37 million
Book Value
$0.27 per share

Miscellaneous

Free Float
178,604,000
Market Cap
$340.20 million
Optionable
Optionable
Beta
1.31

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

CERS Stock Analysis - Frequently Asked Questions

Should I buy or sell Cerus stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CERS shares.
View CERS analyst ratings
or view top-rated stocks.

What is Cerus' stock price target for 2024?

3 brokerages have issued 1 year target prices for Cerus' shares. Their CERS share price targets range from $2.50 to $5.00. On average, they predict the company's stock price to reach $3.83 in the next year. This suggests a possible upside of 108.3% from the stock's current price.
View analysts price targets for CERS
or view top-rated stocks among Wall Street analysts.

How have CERS shares performed in 2024?

Cerus' stock was trading at $2.16 at the beginning of the year. Since then, CERS stock has decreased by 14.8% and is now trading at $1.84.
View the best growth stocks for 2024 here
.

When is Cerus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our CERS earnings forecast
.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) issued its earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.01. The biotechnology company earned $38.37 million during the quarter, compared to analyst estimates of $36.40 million. Cerus had a negative trailing twelve-month return on equity of 58.65% and a negative net margin of 19.27%.

What ETFs hold Cerus' stock?

ETFs with the largest weight of Cerus (NASDAQ:CERS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG).ARK Innovation ETF (ARKK).

What guidance has Cerus issued on next quarter's earnings?

Cerus issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $172.0 million-$175.0 million, compared to the consensus revenue estimate of $190.9 million.

What is William M. (Obi) Greenman's approval rating as Cerus' CEO?

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

Who are Cerus' major shareholders?

Cerus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.40%), Nikko Asset Management Americas Inc. (4.19%), Sumitomo Mitsui Trust Holdings Inc. (4.28%), Wasatch Advisors LP (3.47%), Silvercrest Asset Management Group LLC (1.46%) and Assenagon Asset Management S.A. (0.61%). Insiders that own company stock include Ann Lucena, Carol Moore, Chrystal Jensen, Chrystal Menard, Daniel N Swisher Jr, Eric Bjerkholt, Gail Schulze, Hua Shan, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends
.

How do I buy shares of Cerus?

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CERS) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners